For example, our study suggests enhanced killing of GBM progenitors by ZIKV when given with inhibitors of Type 1 interferon (e.g., IFNAR1 blocking antibody anifrolumab (Peng et al., 2015), TYK2 inhibitor deucravacitinib (Papp et al., 2018) and/or inhibitors of JAK-STAT signaling such as ruxolitinib (Quintás-Cardama et al., 2010), which could be delivered with virus locally to the tumour resection cavity to minimise systemic side effects. The gene discussed is SOAT1; the disease is neoplasm.